Summit Therapeutics Inc.
SMMT
$16.18
$0.060.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 445.48% | 399.25% | 2,509.44% | 35.34% | 22.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.80% | 301.20% | 1,174.24% | 57.71% | 81.20% |
| Operating Income | -242.80% | -301.20% | -1,174.24% | -57.71% | -81.20% |
| Income Before Tax | -258.11% | -312.05% | -836.84% | -44.72% | -67.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -258.11% | -312.05% | -836.84% | -44.72% | -67.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.11% | -312.05% | -836.84% | -44.72% | -67.37% |
| EBIT | -242.80% | -301.20% | -1,174.24% | -57.71% | -81.20% |
| EBITDA | -242.85% | -301.26% | -1,174.73% | -57.75% | -81.29% |
| EPS Basic | -244.46% | -302.84% | -793.08% | -37.64% | -59.00% |
| Normalized Basic EPS | -244.32% | -302.69% | -1,087.28% | -37.73% | -59.20% |
| EPS Diluted | -219.08% | -289.75% | -746.44% | -45.40% | -71.65% |
| Normalized Diluted EPS | -244.32% | -302.69% | -1,087.28% | -37.73% | -59.20% |
| Average Basic Shares Outstanding | 3.95% | 2.31% | 4.90% | 5.17% | 5.27% |
| Average Diluted Shares Outstanding | 3.95% | 2.31% | 4.90% | 5.17% | 5.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |